nova history

1989

Incorporated Nova Laboratories Sdn. Bhd.

1997

Commenced small scale R&D on Phyllanthus niruri, traditionally used for the treatment of liver diseases.

2002

Received approval from National Pharmaceutical Regulatory Agency (NPRA) of the Ministry of Health (MOH) Malaysia to market and sell our Hepar-P Capsule.

2004

Successfully developed and sold our own sustained-release glucosamine caplet in Malaysia.

2006

Awarded the Bionexus Status by Malaysian Biotechnology Corporation (MBC), now known as Malaysia Bioeconomy Development Corporation.

2007

Granted a patent by Intellectual Property Corporation of Malaysia (MyIPO) for the herbal composition of Phyllanthus niruri extract used in our Hepar-P Capsule. Our Hepar-P Capsule was approved by Ministry of Health (MOH) Malaysia for use in government hospitals.

2008

Developed the Actisof technology to enhance the absorption of oil-based ingredients, used in all our softgel products.

2009

Granted another patent by Intellectual Property Corporation of Malaysia (MyIPO) for the standardized composition of Phyllanthus niruri extract used in our Hepar-P Capsule.

2011

Appointed as an anchor company under the National Key Economic Areas (NKEA) Programme to develop ‘High-Value Herbal Products’ as part of the EPP1.

2015

Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.

2016

Pilot-scale trial of vegetable softgel from seaweed extract as an alternative to gelatin softgel.

2017

Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.